



United States of America
FEDERAL TRADE COMMISSION
WASHINGTON, DC 20580

January 4, 2013

Jonathan Sallet, Esq.
O'Melveny & Myers LLP
1625 Eye Street, NW
Washington, DC 20006

Re: Proposed Acquisition of Complete Genomics, Inc. by Wang Jian (BGI-Shenzhen), File No. 131 0003

Dear Mr. Sallet:

The Commission has been conducting an investigation to determine whether the proposed acquisition of Complete Genomics, Inc. by Wang Jian (BGI-Shenzhen) may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Richard C. Donohue
Acting Secretary